Actualizing the Untapped Potential of the Innate Immune System

Affimed’s approach to advancing immuno-oncology

read more



ASCO 2020 Annual Meeting

May 29 - June 2, 2020 (TBD)

more events

Our Mission

We are a team of innate immunity experts unrelenting in our efforts to change the meaning of cancer

With our differentiated approach to arming the body’s innate immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.

read more

Affimed (NASDAQ: AFMD) pioneers immune cell engagement, employing its insights and scientific expertise to harness the body’s innate immune systems in the fight against cancer and other life-threatening diseases. Our proprietary ROCK® (Redirected Optimized Cell Killing) platform allows for the modular design of tetravalent bi- and multi-specific antibodies, including first-in-class innate and adaptive cell engager products.

read less

Our Approach

Redirecting innate cells to recognize and kill tumor cells

We are actualizing the next advancement in immuno-oncology (I-O) through our proprietary ROCK® platform, which stands for Redirected Optimized Cell Killing. Our new approach to build ROCK® based innate cell engagers aims to treat a broad range of hematologic and solid tumors by countering tumor immune evasion through activating a patient’s own innate immune system.

read more about our approach

Our Pipeline

Targeting hematological and solid tumors with differentiated and versatile innate cell engagers

Our ROCK® platform-designed tetravalent bispecific innate cell engagers are being studied in a number of clinical and preclinical programs. These innate cell engagers are the first to demonstrate a favorable safety profile and promising signs of therapeutic efficacy.

learn more about our pipeline

Innate Cell Engagers


Disease Target CD30
Peripheral T cell lymphoma (AFM13-202)
Phase 2
Transformed mycosis fungoides (AFM13-202)
Phase 2
CD30-positive T cell lymphoma (AFM13-102)
Phase 2
HL (post BV and post anti-PD-1) (AFM13-201)
Phase 2

AFM13 + adoptive NK cells

Disease Target CD30
CD30-positive lymphoma (AFM13-104)
Phase 1

AFM13 + anti-PD-1

Disease Target CD30
Hodgkin lymphoma (post BV) (AFM13-103)
Phase 1


Disease Target EGFR
Solid tumors (AFM24-101)
Phase 1


Disease Target BCMA
Multiple Myeloma

AFM28 and AFM32

Disease Target Undisclosed
Multiple Indications


Disease Target Undisclosed
Multiple Programs
Affimed programs
Partnered programs

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.